Vistin Pharma ASA (VISTN) - Total Assets
Based on the latest financial reports, Vistin Pharma ASA (VISTN) holds total assets worth Nkr421.72 Million NOK (≈ $44.38 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Vistin Pharma ASA to assess the company's total reinvestment commitment from operating cash flow.
Vistin Pharma ASA - Total Assets Trend (2016–2024)
This chart illustrates how Vistin Pharma ASA's total assets have evolved over time, based on quarterly financial data. Check VISTN operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Vistin Pharma ASA - Asset Composition Analysis
Current Asset Composition (December 2024)
Vistin Pharma ASA's total assets of Nkr421.72 Million consist of 37.2% current assets and 62.8% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 3.3% |
| Accounts Receivable | Nkr44.28 Million | 11.5% |
| Inventory | Nkr76.67 Million | 19.9% |
| Property, Plant & Equipment | Nkr0.00 | 0.0% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Vistin Pharma ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VISTN market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vistin Pharma ASA's current assets represent 37.2% of total assets in 2024, a decrease from 80.8% in 2016.
- Cash Position: Cash and equivalents constituted 3.3% of total assets in 2024, down from 28.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 19.9% of total assets.
Vistin Pharma ASA Competitors by Total Assets
Key competitors of Vistin Pharma ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.03 Billion |
|
Haleon plc
NYSE:HLN
|
USA | $32.57 Billion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $36.83 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601
|
China | CN¥13.99 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
Vistin Pharma ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.73 | 1.57 | 4.82 |
| Quick Ratio | 0.94 | 0.87 | 4.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Nkr76.64 Million | Nkr55.83 Million | Nkr130.42 Million |
Vistin Pharma ASA - Advanced Valuation Insights
This section examines the relationship between Vistin Pharma ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.86 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -4.6% |
| Total Assets | Nkr384.94 Million |
| Market Capitalization | $96.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vistin Pharma ASA's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Vistin Pharma ASA's assets decreased by 4.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Vistin Pharma ASA (2016–2024)
The table below shows the annual total assets of Vistin Pharma ASA from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr384.94 Million ≈ $40.51 Million |
-4.57% |
| 2023-12-31 | Nkr403.40 Million ≈ $42.45 Million |
-0.94% |
| 2022-12-31 | Nkr407.21 Million ≈ $42.85 Million |
+22.23% |
| 2021-12-31 | Nkr333.15 Million ≈ $35.06 Million |
+3.49% |
| 2020-12-31 | Nkr321.92 Million ≈ $33.87 Million |
-36.15% |
| 2019-12-31 | Nkr504.17 Million ≈ $53.05 Million |
+0.82% |
| 2018-12-31 | Nkr500.06 Million ≈ $52.62 Million |
+115.78% |
| 2017-12-31 | Nkr231.75 Million ≈ $24.39 Million |
-17.09% |
| 2016-12-31 | Nkr279.52 Million ≈ $29.41 Million |
-- |
About Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is based in Oslo, Norway.